Merck MRK announced developmental updates related to its two COVID-19 therapy candidates — molnupiravir and MK-7110. The company plans to start enrollment in the phase III portion of a phase II/III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback